PTAB Upholds Validity Of 5 Patents For Pfizer's Toviaz
The Patent Trial and Appeal Board on Wednesday upheld the validity of five UCB Pharma GmbH patents licensed to Pfizer Inc. for its overactive-bladder drug Toviaz, reasoning that challenger Mylan Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article